Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.
J Clin Densitom
; 24(2): 338-340, 2021.
Article
em En
| MEDLINE
| ID: mdl-33218880
Rebound-associated vertebral fractures (RAVFs) could occur in a minority of the patients who discontinue denosumab. In such patients, denosumab is often reinstituted to rapidly suppress bone turnover and avert the risk of additional fractures. Herein we report the cases of 2 patients who sustained RAVFs, and in whom resuming denosumab treatment did not avert the occurrence of new RAVFs a few months later, despite the suppression of bone turnover markers. It seems that denosumab reinstitution cannot completely eliminate the risk of new RAVFs and that the rebound of bone turnover may not be the sole mechanism to explain this phenomenon.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Osteoporose Pós-Menopausa
/
Fraturas da Coluna Vertebral
/
Conservadores da Densidade Óssea
Tipo de estudo:
Risk_factors_studies
Limite:
Female
/
Humans
Idioma:
En
Revista:
J Clin Densitom
Assunto da revista:
ORTOPEDIA
Ano de publicação:
2021
Tipo de documento:
Article